At Transpharmation, our multi-faceted approach combines the use of naturally occurring deficits in aged animals along with pharmacological intervention to mimic aspects of the disease such as cognitive deficits, and sleep disruption. Furthermore, using our extensive biomarker platform we can profile translational disease markers such as TAU/phospho-TAU in both rodent and human tissue (via our CNS biobank) and assess the role of neuroinflammatory markers, such as cytokines, chemokines and microglia in AD disease pathology.

Examples of the models we offer include:


pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.